Abstract
Background: Z-endoxifen is the most potent of the metabolites of tamoxifen, and has the potential to be more effective than tamoxifen because it bypasses potential drug resistance mechanisms attributable to patient variability in the expression of the hepatic microsomal enzyme CYP2D6. 18F-FES is a positron emission tomography (PET) imaging agent which selectively binds to estrogen receptor alpha (ER-α) and has been used for non-invasive in vivo assessment of ER activity in tumors. This study utilizes 18F-FES PET imaging as a pharmacodynamic biomarker in patients with ER+ tumors treated with Z-endoxifen. Methods: Fifteen patients were recruited from a parent therapeutic trial of Z-endoxifen and underwent imaging with 18F-FES PET at baseline. Eight had positive lesions on the baseline scan and underwent follow-up imaging with 18F-FES 1–5 days post administration of Z-endoxifen. Results: Statistically significant changes (p = 0.0078) in standard uptake value (SUV)-Max were observed between the baseline and follow-up scans as early as 1 day post drug administration. Conclusion: F-FES PET imaging could serve as a pharmacodynamic biomarker for patients treated with ER-directed therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 500-508 |
| Number of pages | 9 |
| Journal | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 44 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2017 |
| Externally published | Yes |
Funding
This project was funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.
| Funders | Funder number |
|---|---|
| Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health | HHSN261200800001E |
| National Institute of Health-National Cancer Institute | ZIABC011078 |
Keywords
- F-FES
- Fluoroestradiol
- Pharmacodynamic marker
- Positron emission tomography (PET)
- Z-endoxifen
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Fingerprint
Dive into the research topics of 'Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS